公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
2021 | Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | YU-YUN SHAO ; Wang, Shen-Yung; Lin, Shi-Ming; Chen, Kuan-Yang; Tseng, Jeng-Hwei; MING-CHIH HO ; Lee, Rheun-Chuan; PO-CHIN LIANG ; Liao, Li-Ying; KAI-WEN HUANG ; Hu, Jui-Ting; JA-DER LIANG ; Kee, Kwong-Ming; Lin, Chih-Lin; Wang, Chung-Kwe; Lu, Sheng-Nan; Wang, Jing-Houng; Lee, Wei-Chen; CHIEN-HUNG CHEN ; CHUN-JEN LIU ; Huang, Yi-Hsiang; Wang, Chia-Chi; Wang, Tsang-En; Chuang, Po-Heng; Dai, Chia-Yen; CHIUN HSU ; Chen, San-Chi; Hsieh, Chia-Hsun | Journal of the Formosan Medical Association | 67 | 65 | |
2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | | |
2007 | Molecular targeted therapy for advanced hepatocellular carcinoma | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Targeted Oncology | 6 | 4 | |
2010 | Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology | 62 | 54 | |
2022 | Moving from tangibility toward digitalization: investigating team dynamics and facilitator support among medical students in conventional and digital small-group tutorials | CHIA-TER CHAO ; YEN-LIN CHIU ; CHIAO-LING TSAI ; MONG-WEI LIN ; CHIH-WEI YANG ; CHAO-CHI HO ; YEN-YUAN CHEN ; CHIUN HSU ; HUEY-LING CHEN | BMC medical education | 1 | 2 | |
2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
2020 | A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study | Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG ; Hsiao H.-H.; Shen W.-C.; CHIUN HSU ; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | European Journal of Cancer | 11 | 9 | |
2020 | Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study | Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG ; CHIUN HSU ; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | Liver International | 6 | 5 | |
2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
1997 | MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer | CHIUN HSU ; KUN-HUEI YEH ; RUEY-LONG HONG ; CHIH-HSIN YANG ; Lin M.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | Journal of the Formosan Medical Association | 4 | 3 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 171 | 154 | |
2017 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. | The Lancet | 3010 | 2816 | |
2024 | Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 | El-Khoueiry, A B; Trojan, J; Meyer, T; Yau, T; Melero, I; Kudo, M; CHIUN HSU ; Kim, T-Y; Choo, S-P; Kang, Y-K; Yeo, W; Chopra, A; Soleymani, S; Yao, J; Neely, J; Tschaika, M; Welling, T H; Sangro, B | Annals of oncology : official journal of the European Society for Medical Oncology | 1 | | |
2020 | Novel systemic therapy for hepatocellular carcinoma | Dong Y.; TSUNG-HAO LIU ; Yau T.; CHIUN HSU | Hepatology International | 13 | 11 | |
2009 | Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival | Ying-Chun Shen ; Hu F.-C.; YUNG-MING JENG ; YU-TING CHANG ; ZHONG-ZHE LIN ; MING-CHU CHANG ; CHIUN HSU ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 21 | 20 | |
2020 | An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas | Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; CHIUN HSU ; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. | Oncologist | 7 | 6 | |
2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
2009 | Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma | Jan Y.-J.; BOR-SHENG KO ; CHIUN HSU ; Chang T.-C.; Chen S.-C.; Wang J.; Liou J.-Y. | Human Pathology | 28 | 27 | |
2011 | Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma | BOR-SHENG KO ; Chang T.-C.; CHIUN HSU ; YAO-CHANG CHEN ; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J.; Liou J.-Y. | Histopathology | 49 | 46 | |